Sadik Kassim, PhD

Sadik Kassim, PhD, serves as Chief Technology Officer of Genomic Medicines for the Life Sciences companies at Danaher Corporation. He has extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. In his prior roles, Dr. Kassim and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah®, Yescarta®, and Tecartus®. Prior to Danaher, Dr. Kassim was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the company’s CAR-T efforts. Previously, Dr. Kassim served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. As the Chief Scientific Officer at MustangBio, Dr. Kassim managed the foundational build-out of the company’s preclinical and manufacturing activities. Earlier in his career, he was Head of Early Analytical Development for Novartis’ Cell and Gene Therapies Unit and worked on research teams as post-doctoral research fellow at the National Cancer Institute with Dr. Steven Rosenberg, the University of Pennsylvania Gene Therapy Program with Dr. Jim Wilson, and Johnson and Johnson’s Immunology Discovery group. He received his PhD in microbiology and immunology from Louisiana State University and his BS in cellular and molecular biology from Tulane University.